Found: 4
Select item for more details and to access through your institution.
Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 3, p. 263, doi. 10.1007/s40261-021-01115-5
- By:
- Publication type:
- Article
Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo‐controlled study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 5, p. 683, doi. 10.1111/head.14460
- By:
- Publication type:
- Article
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article